Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1993-08-27
1994-12-13
Evans, Joseph E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540584, A61K 3155, A61K 31435, C07D47108, C07D22100
Patent
active
053730038
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This invention relates to novel 1-azabicyclo[3.2.2]-nonan-3-amine derivatives.
The compounds of the invention have the ability to antagonize substance P. They are, therefore, useful in treating conditions such as intestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine. The present invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treating the foregoing conditions.
E. J. Warawa in U.S. Pat. No. 3,560,510 refers to certain 3-amino-2-benzhydrylquinuclidines as being useful as diuretic agents, with the corresponding unsubstituted 3-benzylamino compounds acting as intermediates for same. Additionally, E. J. Warawa et al. In the Journal of Medicinal Chemistry, Vol. 18, p. 587 (1975) extends this work to other members of the series wherein the 3-amino moiety is either ethylamino, beta-phenylethylamino, beta-isopropyl-amino or 2-furfurylamino, but in no instance is there any substitution on the phenyl group itself and the 2-benzhydryl moiety is always symmetrically substituted (or unsubstituted). Neither of the aforementioned documents teaches or suggests any of these compounds to be useful as substance P antagonists.
PCT Patent Application PCS/US 89/05338, filed Nov. 20, 1989, now Published PCT International Patent Application No. WO090/05729 (published May 31, 1990) in addition to also being U.S. Pat. No. 5,162,339, refers to cis-3-[(cyclic)methylamino]-2-[(alpha-substituted)arylmethyl]quinuclidines , 3-[(cyclic)methylamino]-2-[(alpha-substituted)arylmethyl]quinuclidines and cis-3-[(cyclic)methyleneamino]-2-[alpha-substituted)-arylmethyl]quinuc lidinesandstates that they are useful as substance P antagonists. PCT Patent Application PCT/US 90/00116, now Published PCT International Patent Application No. W091/09844 (published Jul. 7, 1991), refers to carbotricyclic ring systems wherein one of the rings is substituted with an amino group and wherein one carbon atom in each of two of the rings may be replaced by a hetero atom, and states that they are useful as substance P antagonists.
U.S. patent application Ser. No. 07/557,442 filed Jul. 23, 1990 and now abandoned in favor of continuation-in-part U.S. patent application Ser. No. 988,125, filed May 14, 1991, which corresponds to PCT Patent Application PCT/US/91/03369, filed May 15, 1991 and now Published PCT International Patent Application No. WO092/01688 (published Feb. 6, 1992), refers to azatricyclic quinuclidine derivatives and states that such compounds are useful as substance P antagonists.
Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt stimulatory action on smooth muscle tissue. More specifically, substance P is a pharmacologically-active neuropeptide that is produced in mammals (having originally been isolated from gut) and possesses a characteristic amino acid sequence that is illustrated by D. F. Veber et al. in U.S. Pat. No. 4,680,283. The wide involvement of substance P and other tachykinins in the pathophysiology of numerous diseased has been amply demonstrated in the art. For instance, substance P has recently been shown to be involved in the transmission of pain or migraine [see B. E. B. Sandberg et al., Journal of Medicinal Chemistry, Vol. 25, p. 1009 (1982)], as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, respective, and in gastrointestinal disorders and diseases of the GI tract, like ulcerative colitis and Crohn's disease, etc. (see D. Regoli in "Trends in Cluster Headache,".pi.Edited by F. Sicuteri et al., Elsevier Scientific Publishers, Amsterdam, 1987, pp. 85-95).
SUMMARY OF THE INVENTION
The present invention relates to compounds of the formula ##STR2## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are each independently selected from hydrogen fluorine, chlorine, bromine, t
REFERENCES:
patent: 3560510 (1971-02-01), Warawa
patent: 4775668 (1988-10-01), Jefson et al.
patent: 4910193 (1990-03-01), Buchheit
patent: 5106843 (1992-04-01), Ward et al.
patent: 5202318 (1993-04-01), Berger et al.
Evans Joseph E.
Ginsburg Paul H.
Pfizer Inc.
Richardson Peter C.
LandOfFree
1-azabicyclo[3.2.2]nonan-3-amine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-azabicyclo[3.2.2]nonan-3-amine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-azabicyclo[3.2.2]nonan-3-amine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1193568